Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
ACS Medicinal Chemistry Letters|June 18, 2021
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met InhibitorsQing Tang, Alex M Aronov, David D Deininger, et al.Plos Pathogens|February 13, 2015
Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environmentBrian C VanderVen, Ruth J Fahey, Wonsik Lee, et al.Bioorganic & Medicinal Chemistry Letters|August 6, 2017
2-N-Arylthiazole inhibitors of Mycobacterium tuberculosisMichael P Clark, Tiansheng Wang, Emanuele Perola, et al.Bioorganic & Medicinal Chemistry Letters|April 2, 2014
Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacyEmanuele Perola, Dean Stamos, Anne-Laure Grillot, et al.Bioorganic & Medicinal Chemistry Letters|March 10, 2004
Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimizationRobert B Perni, Janos Pitlik, Shawn D Britt, et al.Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Inhibitors of hepatitis C virus NS3.4A protease 1. Non-charged tetrapeptide variantsRobert B Perni, Shawn D Britt, John C Court, et al.Bioorganic & Medicinal Chemistry Letters|March 31, 2004
Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variantsRobert B Perni, Luc J Farmer, Kevin M Cottrell, et al.Journal of Medicinal Chemistry|August 12, 2008
Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationshipsPaul S Charifson, Anne-Laure Grillot, Trudy H Grossman, et al.Pageof 1